Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia. Show more
Location: Level 10, Kuala Lumpur, 592000, Malaysia | Website: https://www.cyclacel.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
17.21M
52 Wk Range
$3.08 - $597.60
Previous Close
$7.68
Open
$7.53
Volume
30,970
Day Range
$7.26 - $7.59
Enterprise Value
12.78M
Cash
4.275M
Avg Qtr Burn
-2.182M
Insider Ownership
75.19%
Institutional Own.
0.99%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Oral Fadraciclib (CDK2 & CDK9) Details Solid tumor/s, Lymphoma, Cancer | Phase 2 Data readout | |
Oral Plogosertib Details Lymphoma, Solid tumor/s | Phase 1 Data readout |